A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT03934372 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose

NCT03933852 ·Status: UNKNOWN

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

NCT05306301 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04501614 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT04070443 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

NCT04554459 ·Status: TERMINATED ·Phase: PHASE2

Iclusig PMS in CML or Ph+ALL Patients

NCT03709017 ·Status: UNKNOWN

Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia

NCT04709731 ·Status: UNKNOWN ·Phase: PHASE2

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

NCT02455024 ·Status: TERMINATED

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01667133 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

NCT01310010 ·Status: COMPLETED ·Phase: PHASE2

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

NCT04233346 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

NCT01344876 ·Status: COMPLETED ·Phase: PHASE1

Study in Adult Ph-positive ALL

NCT04688983 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase

NCT00514969 ·Status: COMPLETED ·Phase: PHASE2

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

NCT03677596 ·Status: COMPLETED ·Phase: PHASE4

Expanded Access Program of Ponatinib

NCT01592136 ·Status: APPROVED_FOR_MARKETING

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

NCT02361346 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

NCT02467270 ·Status: COMPLETED ·Phase: PHASE2

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

NCT01746836 ·Status: RECRUITING ·Phase: PHASE2

Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

NCT00287105 ·Status: COMPLETED ·Phase: PHASE2

Study in Patients With Chronic Leukemia

NCT03807479 ·Status: TERMINATED ·Phase: PHASE2

Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase

NCT06119269 ·Status: RECRUITING

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

NCT04030195 ·Status: COMPLETED ·Phase: PHASE1/PHASE2